Moleculin Biotech MBRX 深 滬
等待開盤 09-25 09:30:00 美东时间
0.5669
+0.039
+7.39%
華盛通- 最 高0.57
- 今 開0.52
- 成交量 53.80万股
- 最 低 0.51
- 昨 收 0.5279
- 總市值 1.16万
- 52周最高 15.75
- 市盈率 靜 --
- 換手率 2639.03%
- 52周最低 0.1614
- 委 比 4.72%
- 總股本 2.04万
- 歷史最高 21555.00
- 量 比 0.21
- 振 幅 11.37%
- 歷史最低 0.1614
- 每 手 1
- 風險率 3.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股异动丨Moleculin Biotech盘前续涨约6%，临床数据预期与学术会议催化
格隆汇9月15日｜美股生物医药股Moleculin Biotech(MBRX.US盘前继续上涨约6%，延续了前一交易日的反弹势头。 消息面上，公司于9月14日宣...
09-15 17:08
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
Moleculin Biotech, Inc. announced that its pre-recorded presentation from the H.C. Wainwright Global Investment Conference is now available on-demand. The presentation, led by CEO Walter Klemp, covers the company's recent developments, including its lead program, Annamycin, a potential treatment for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Annamycin is currently in Phase 2/3 trials. The co...
09-11 12:30
Moleculin Biotech Updates Investors with New Presentation
Moleculin Biotech ( ($MBRX) ) has shared an update. On August 31, 2026, Molecul...
09-01 05:53
美股大行评级 | 潜在涨幅768.26%！Ascendiant Capital维持RenovoRx(RNXT)"买入"评级，目标价上调至14.5美元
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从14美元升至14.5美元；HC Wainwright & Co.：维持Generate Biomedicines"买入"评级，目标价从25美元升至30美元
08-31 18:14
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3
HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $22 to $3.
08-28 19:10
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
Moleculin Biotech, Inc. participated in the Virtual Investor “Why Now” on-demand conference, highlighting its clinical progress and long-term opportunity. Walter Klemp, CEO, discussed encouraging interim results from the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin for relapsed or refractory acute myeloid leukemia (AML). The presentation emphasized Annamycin's differentiated clinical profile, enrollment progress, commercial opportunity, a...
08-27 13:01
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share from the same period last year.
08-14 20:48
Moleculin Biotech completes $9.3M equity financing
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On July 31, 2026, Mol...
08-04 06:22
Moleculin Announces Pricing of $9.3 Million Public Offering
Moleculin Biotech announced a public offering of 12.4 million shares and warrants for up to 37.1 million shares at $0.75 per share, expected to close on August 3. Proceeds will fund the clinical development of Annamycin and working capital. Roth Capital Partners is the placement agent, and Maxim Group is the financial advisor. Annamycin is in Phase 3 for relapsed/refractory acute myeloid leukemia and soft tissue sarcoma.
07-31 14:12
Moleculin Biotech shares are trading lower. The company announced a best‑efforts public offering of stock and warrants, including pre‑funded options to cap ownership.
Moleculin Biotech shares are trading lower. The company announced a best‑efforts public offering of stock and warrants, including pre‑funded options to cap ownership.
07-30 02:57
